The first in-depth look Roche’s anti-CD20 bispecific, mosunetuzumab, reveals some very encouraging response rates, even in patients who failed Car-T therapy.
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.